Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-10-03

Clinical Trial Update: Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluated desloratadine at 5, 10, and 20 mg in patients with cold urticaria; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Desloratadine (desloratadine)

Snippet

Sponsor: Marcus Maurer | Conditions: Urticaria | Phase 4 | Status: COMPLETED